COPD Patients Clinical Trial
Official title:
A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.
Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world. Acute exacerbations of COPD (AECOPD) are the most important events in the course of the disease because they negatively impact health status, life quality, disease progression, patients survival and economic and social burden. Reducing frequency of AECOPD is the key goal of management for COPD. Since respiratory viral infections are the mainly trigger of AECOPD, anti-viral therapy would be the affective method to prevent the exacerbation or reduce the attack severity. However, there are no positive study results of treating or preventing AECOPD used by current anti-viral drugs approved by FDA so far. Arbidol is a non-nucleoside antiviral drug. It inhibits viral DNA and RNA synthesis by inhibiting fusion of viral lipid vesicle membrane with host cell membranes. Arbidol has broad-spectrum antiviral activity. In addition to inhibition of influenza virus, it against a variety of viruses including respiratory syncytial disease (RSV), parainfluenza virus, human rhinovirus, coxsackie virus (CV), adenovirus (ADV) and so on. In recent years, some fundamental and clinical researches have shown that arbidol has a significant role in prevention and treatment of influenza virus and other acute respiratory viral infections. Therefore, the investigators speculate that Arbidol will effectively control COPD combined with upper respiratory virus infection, thereby reducing acute exacerbations of COPD. This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 52-week study. The purpose of this study is to evaluate the efficacy and safety of arbidol in improving the frequency and extent of moderate or severe acute exacerbations in patients with COPD. Eligible subjects will be randomly assigned to treatment group or placebo group at a 2:1 ratio. Subjects of treatment group receive an on-demand arbidol 200 mg three times per day while placebo group receives matched placebo. When the subject has a new respiratory infection, original respiratory symptoms worsen, or fever (the lower body temperature is greater than 37.3℃), oral medication is given immediately. The subjects are required to receive the first dose of drug within 8 hours after the symptoms of upper respiratory tract infection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05980611 -
Nasal IL 1 Beta ,IL 3 Level and Their Effects in COPD Patients
|
||
| Recruiting |
NCT00949195 -
Pulmonary Arterial Pressure Response During Exercise
|
N/A | |
| Completed |
NCT06128902 -
The Effect of Home-Based Monitoring, Exercise Training
|
N/A | |
| Completed |
NCT01475812 -
Daily Activities Are Sufficient to Induce Dynamic Pulmonary Hyperinflation and Dyspnea in Chronic Obstructive Pulmonary Disease Patients
|
N/A | |
| Completed |
NCT02157935 -
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
|
Phase 3 | |
| Completed |
NCT01183052 -
Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients
|
N/A | |
| Withdrawn |
NCT00180622 -
Markers for Chronic Obstructive Pulmonary Disease (COPD)
|
||
| Completed |
NCT04869033 -
Effects of Farinelli's Breathing Exercise in COPD Patients
|
N/A | |
| Completed |
NCT02099279 -
Prognostic Value Cardiac Dysfunction Assessed by Bedside Echocardiography in Critically Ill COPD Patients Requiring Mechanical Ventilation
|
N/A | |
| Withdrawn |
NCT00361426 -
EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients
|
N/A | |
| Recruiting |
NCT03774238 -
Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients
|
N/A |